SPRY4 and cholangiocarcinoma: The data confirmed that SPRY4-IT1 expression could be regarded as an independent predictor of an adverse PFS (P = 0.018) and OS (P = 0.027) in CCA patients, in addition to TNM stage (P = 0.005, Additional file 3: Table S3).